Skip to main content
Top
Published in: Annals of Hematology 12/2011

01-12-2011 | Original Article

Chronic lymphocytic leukemia cells induce anti-apoptotic effects of bone marrow stroma

Authors: Márk Plander, Peter Ugocsai, Silvia Seegers, Evelyn Orsó, Albrecht Reichle, Gerd Schmitz, Ferdinand Hofstädter, Gero Brockhoff

Published in: Annals of Hematology | Issue 12/2011

Login to get access

Abstract

The prolonged life span of chronic lymphocytic leukemia (CLL) cells in vivo is assumed to depend on the surrounding microenvironment since this biologic feature is lost in vitro. We studied here the molecular interactions between CLL cells and their surrounding stroma to identify factors that help CLL cells to resist apoptosis. Sorted CLL cells from 21 patients were cultured in vitro on allogenous, normal bone marrow stromal cells (BMSCs) in the presence/absence of CD40 ligand or in culture medium alone. Surface and mRNA expression of interaction molecules, cytokine production, and apoptosis rate was measured by flow cytometric, real-time PCR and standard immunologic assays. The interaction between CLL cells and BMSCs rescued CLL cells from apoptosis. BMSCs co-cultured with CLL cells showed a strong increase in IL-8 and IL-6 secretion and up-regulated the expression of ICAM-1 and CD40 mRNA. The mRNA expression of CXCL12 and VCAM1 remained unchanged. In turn, CLL cells in interaction with BMSCs significantly up-regulated the expression of CD18 and CD49d that are ligands for the critical adhesion molecules on BMSCs. As a validation of the in vitro data, we found a significant higher expression of CD49d on CLL cells in bone marrow aspirates compared to peripheral blood CLL cells in patient samples. Up-regulation of adhesion molecules and their ligands in CLL–BMSCs interaction along with the increased cytokine production of BMSCs indicate a strong effect of CLL cells on BMSCs in favor of their apoptosis resistance.
Appendix
Available only for authorised users
Literature
1.
go back to reference Kay NE, Hamblin TJ, Jelinek DF, Dewald GW, Byrd JC, Farag S et al (2002) Chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 193–213 Kay NE, Hamblin TJ, Jelinek DF, Dewald GW, Byrd JC, Farag S et al (2002) Chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 193–213
2.
go back to reference Kitada S, Andersen J, Akar S, Zapata JM, Takayama S, Krajewski S et al (1998) Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses. Blood 91(9):3379–3389PubMed Kitada S, Andersen J, Akar S, Zapata JM, Takayama S, Krajewski S et al (1998) Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses. Blood 91(9):3379–3389PubMed
3.
go back to reference Collins RJ, Verschuer LA, Harmon BV, Prentice RL, Pope JH, Kerr JF (1989) Spontaneous programmed death (apoptosis) of B-chronic lymphocytic leukaemia cells following their culture in vitro. Br J Haematol 71(3):343–350PubMedCrossRef Collins RJ, Verschuer LA, Harmon BV, Prentice RL, Pope JH, Kerr JF (1989) Spontaneous programmed death (apoptosis) of B-chronic lymphocytic leukaemia cells following their culture in vitro. Br J Haematol 71(3):343–350PubMedCrossRef
4.
go back to reference Lagneaux L, Delforge A, Bron D, de Bruyn C, Stryckmans P (1998) Chronic lymphocytic leukemic B cells but not normal B cells are rescued from apoptosis by contact with normal bone marrow stromal cells. Blood 91(7):2387–2396PubMed Lagneaux L, Delforge A, Bron D, de Bruyn C, Stryckmans P (1998) Chronic lymphocytic leukemic B cells but not normal B cells are rescued from apoptosis by contact with normal bone marrow stromal cells. Blood 91(7):2387–2396PubMed
5.
go back to reference Jewell AP, Lydyard PM, Worman CP, Giles FJ, Goldstone AH (1995) Growth factors can protect B-chronic lymphocytic leukaemia cells against programmed cell death without stimulating proliferation. Leuk Lymphoma 18:159–162PubMedCrossRef Jewell AP, Lydyard PM, Worman CP, Giles FJ, Goldstone AH (1995) Growth factors can protect B-chronic lymphocytic leukaemia cells against programmed cell death without stimulating proliferation. Leuk Lymphoma 18:159–162PubMedCrossRef
6.
go back to reference Reittie JE, Yong KL, Panayiotidis P, Hoffbrand AV (1996) Interleukin-6 inhibits apoptosis and tumour necrosis factor induced proliferation of B-chronic lymphocytic leukaemia. Leuk Lymphoma 22:83–90PubMedCrossRef Reittie JE, Yong KL, Panayiotidis P, Hoffbrand AV (1996) Interleukin-6 inhibits apoptosis and tumour necrosis factor induced proliferation of B-chronic lymphocytic leukaemia. Leuk Lymphoma 22:83–90PubMedCrossRef
7.
go back to reference Schröttner P, Leick M, Burger M (2010) The role of chemokines in B-cell chronic lymphocytic leukemia cells: pathophysiological aspects and clinical impact. Ann Hematol 89(5):437–446PubMedCrossRef Schröttner P, Leick M, Burger M (2010) The role of chemokines in B-cell chronic lymphocytic leukemia cells: pathophysiological aspects and clinical impact. Ann Hematol 89(5):437–446PubMedCrossRef
8.
go back to reference König A, Menzel T, Lynen S, Wrazel L, Rosén A, Al-Katib A, Raveche E, Gabrilove JL (1997) Basic fibroblast growth factor (bFGF) upregulates the expression of bcl-2 in B cell chronic lymphocytic leukemia cell lines resulting in delaying apoptosis. Leukemia 11(2):258–265PubMedCrossRef König A, Menzel T, Lynen S, Wrazel L, Rosén A, Al-Katib A, Raveche E, Gabrilove JL (1997) Basic fibroblast growth factor (bFGF) upregulates the expression of bcl-2 in B cell chronic lymphocytic leukemia cell lines resulting in delaying apoptosis. Leukemia 11(2):258–265PubMedCrossRef
9.
go back to reference Kay NE, Bone ND, Tschumper RC, Howell KH, Geyer SM, Dewald GW, Hanson CA, Jelinek DF (2002) B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules. Leukemia 16(5):911–919PubMedCrossRef Kay NE, Bone ND, Tschumper RC, Howell KH, Geyer SM, Dewald GW, Hanson CA, Jelinek DF (2002) B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules. Leukemia 16(5):911–919PubMedCrossRef
10.
go back to reference Molica S, Vacca A, Ribatti D, Cuneo A, Cavazzini F, Levato D et al (2002) Prognostic value of enhanced bone marrow angiogenesis in early B-cell chronic lymphocytic leukemia. Blood 100(9):3344–3351PubMedCrossRef Molica S, Vacca A, Ribatti D, Cuneo A, Cavazzini F, Levato D et al (2002) Prognostic value of enhanced bone marrow angiogenesis in early B-cell chronic lymphocytic leukemia. Blood 100(9):3344–3351PubMedCrossRef
11.
go back to reference Kay NE, Shanafelt TD, Strege AK, Lee YK, Bone ND, Raza A (2007) Bone biopsy derived marrow stromal elements rescue chronic lymphocytic leukemia B-cells from spontaneous and drug induced cell death and facilitates an “angiogenic switch”. Leuk Res 31(7):899–906PubMedCrossRef Kay NE, Shanafelt TD, Strege AK, Lee YK, Bone ND, Raza A (2007) Bone biopsy derived marrow stromal elements rescue chronic lymphocytic leukemia B-cells from spontaneous and drug induced cell death and facilitates an “angiogenic switch”. Leuk Res 31(7):899–906PubMedCrossRef
12.
go back to reference Chanan-Khan A, Miller KC, Takeshita K, Koryzna A, Donohue K, Bernstein ZP et al (2005) Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL). Blood 106(10):3348–3352PubMedCrossRef Chanan-Khan A, Miller KC, Takeshita K, Koryzna A, Donohue K, Bernstein ZP et al (2005) Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL). Blood 106(10):3348–3352PubMedCrossRef
13.
go back to reference Ferrajoli A, Lee BN, Schlette EJ, O'Brien SM, Gao H, Wen S et al (2008) Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 111(11):5291–5297PubMedCrossRef Ferrajoli A, Lee BN, Schlette EJ, O'Brien SM, Gao H, Wen S et al (2008) Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 111(11):5291–5297PubMedCrossRef
14.
go back to reference Schmid C, Isaacson PG (1994) Proliferation centres in B-cell malignant lymphoma, lymphocytic (B-CLL): an immunophenotypic study. Histopathology 24(5):445–451PubMedCrossRef Schmid C, Isaacson PG (1994) Proliferation centres in B-cell malignant lymphoma, lymphocytic (B-CLL): an immunophenotypic study. Histopathology 24(5):445–451PubMedCrossRef
15.
go back to reference Ghia P, Strola G, Granziero L, Geuna M, Guida G, Sallusto F et al (2002) Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22. Eur J Immunol 32(5):1403–1413PubMedCrossRef Ghia P, Strola G, Granziero L, Geuna M, Guida G, Sallusto F et al (2002) Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22. Eur J Immunol 32(5):1403–1413PubMedCrossRef
16.
go back to reference Vega F, Medeiros LJ, Lang WH, Mansoor A, Bueso-Ramos C, Jones D (2002) The stromal composition of malignant lymphoid aggregates in bone marrow: variations in architecture and phenotype in different B-cell tumours. Br J Haematol 117(3):569–576PubMedCrossRef Vega F, Medeiros LJ, Lang WH, Mansoor A, Bueso-Ramos C, Jones D (2002) The stromal composition of malignant lymphoid aggregates in bone marrow: variations in architecture and phenotype in different B-cell tumours. Br J Haematol 117(3):569–576PubMedCrossRef
17.
go back to reference Plander M, Seegers S, Ugocsai P, Diermeier-Daucher S, Iványi J, Schmitz G, Hofstädter F, Schwarz S, Orsó E, Knüchel R, Brockhoff G (2009) Different proliferative and survival capacity of CLL-cells in a newly established in vitro model for pseudofollicles. Leukemia 23(11):2118–2128PubMedCrossRef Plander M, Seegers S, Ugocsai P, Diermeier-Daucher S, Iványi J, Schmitz G, Hofstädter F, Schwarz S, Orsó E, Knüchel R, Brockhoff G (2009) Different proliferative and survival capacity of CLL-cells in a newly established in vitro model for pseudofollicles. Leukemia 23(11):2118–2128PubMedCrossRef
18.
go back to reference Haniffa MA, Collin MP, Buckley CD, Dazzi F (2009) Mesenchymal stem cells: the fibroblasts' new clothes? Haematologica 94:258–263PubMedCrossRef Haniffa MA, Collin MP, Buckley CD, Dazzi F (2009) Mesenchymal stem cells: the fibroblasts' new clothes? Haematologica 94:258–263PubMedCrossRef
19.
go back to reference Panayiotidis P, Jones D, Ganeshaguru K, Foroni L, Hoffbrand AV (1996) Human bone marrow stromal cells prevent apoptosis and support the survival of chronic lymphocytic leukaemia cells in vitro. Br J Haematol 92(1):97–103PubMedCrossRef Panayiotidis P, Jones D, Ganeshaguru K, Foroni L, Hoffbrand AV (1996) Human bone marrow stromal cells prevent apoptosis and support the survival of chronic lymphocytic leukaemia cells in vitro. Br J Haematol 92(1):97–103PubMedCrossRef
20.
go back to reference Lagneaux L, Delforge A, De Bruyn C, Bernier M, Bron D (1999) Adhesion to bone marrow stroma inhibits apoptosis of chronic lymphocytic leukemia cells. Leuk Lymphoma 35(5–6):445–453PubMedCrossRef Lagneaux L, Delforge A, De Bruyn C, Bernier M, Bron D (1999) Adhesion to bone marrow stroma inhibits apoptosis of chronic lymphocytic leukemia cells. Leuk Lymphoma 35(5–6):445–453PubMedCrossRef
21.
go back to reference Burger JA, Burger M, Kipps TJ (1999) Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. Blood 94(11):3658–3667PubMed Burger JA, Burger M, Kipps TJ (1999) Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. Blood 94(11):3658–3667PubMed
22.
go back to reference Shanafelt TD, Geyer SM, Bone ND, Tschumper RC, Witzig TE, Nowakowski GS et al (2008) CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukemia: a prognostic parameter with therapeutic potential. Br J Haematol 140(5):537–546PubMedCrossRef Shanafelt TD, Geyer SM, Bone ND, Tschumper RC, Witzig TE, Nowakowski GS et al (2008) CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukemia: a prognostic parameter with therapeutic potential. Br J Haematol 140(5):537–546PubMedCrossRef
23.
go back to reference Weber KS, Klickstein LB, Weber C (1999) Specific activation of leukocyte beta2 integrins lymphocyte function-associated antigen-1 and Mac-1 by chemokines mediated by distinct pathways via the alpha subunit cytoplasmic domains. Mol Biol Cell 10(4):861–873PubMed Weber KS, Klickstein LB, Weber C (1999) Specific activation of leukocyte beta2 integrins lymphocyte function-associated antigen-1 and Mac-1 by chemokines mediated by distinct pathways via the alpha subunit cytoplasmic domains. Mol Biol Cell 10(4):861–873PubMed
24.
go back to reference Röpke C, Gladstone P, Nielsen M, Borregaard N, Ledbetter JA, Svejgaard A, Odum N (1996) Apoptosis following interleukin-2 withdrawal from T cells: evidence for a regulatory role of CD18 (beta 2-integrin) molecules. Tissue Antigens 48(2):127–135PubMedCrossRef Röpke C, Gladstone P, Nielsen M, Borregaard N, Ledbetter JA, Svejgaard A, Odum N (1996) Apoptosis following interleukin-2 withdrawal from T cells: evidence for a regulatory role of CD18 (beta 2-integrin) molecules. Tissue Antigens 48(2):127–135PubMedCrossRef
25.
go back to reference Wagner C, Hänsch GM, Stegmaier S, Denefleh B, Hug F, Schoels M (2001) The complement receptor 3, CR3 (CD11b/CD18), on T lymphocytes: activation-dependent up-regulation and regulatory function. Eur J Immunol 31(4):1173–1180PubMedCrossRef Wagner C, Hänsch GM, Stegmaier S, Denefleh B, Hug F, Schoels M (2001) The complement receptor 3, CR3 (CD11b/CD18), on T lymphocytes: activation-dependent up-regulation and regulatory function. Eur J Immunol 31(4):1173–1180PubMedCrossRef
26.
go back to reference Hulkkonen J, Vilpo J, Vilpo L, Koski T, Hurme M (2000) Interleukin-1 beta, interleukin-1 receptor antagonist and interleukin-6 plasma levels and cytokine gene polymorphisms in chronic lymphocytic leukemia: correlation with prognostic parameters. Haematologica 85(6):600–606PubMed Hulkkonen J, Vilpo J, Vilpo L, Koski T, Hurme M (2000) Interleukin-1 beta, interleukin-1 receptor antagonist and interleukin-6 plasma levels and cytokine gene polymorphisms in chronic lymphocytic leukemia: correlation with prognostic parameters. Haematologica 85(6):600–606PubMed
27.
go back to reference Meinhardt G, Wendtner CM, Hallek M (1999) Molecular pathogenesis of chronic lymphocytic leukemia: factors and signaling pathways regulating cell growth and survival. J Mol Med 77(2):282–293, ReviewPubMedCrossRef Meinhardt G, Wendtner CM, Hallek M (1999) Molecular pathogenesis of chronic lymphocytic leukemia: factors and signaling pathways regulating cell growth and survival. J Mol Med 77(2):282–293, ReviewPubMedCrossRef
28.
go back to reference Springer TA (1994) Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 76(2):301–314PubMedCrossRef Springer TA (1994) Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 76(2):301–314PubMedCrossRef
29.
go back to reference Burger JA, Kipps TJ (2006) CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood 107(5):1761–1767PubMedCrossRef Burger JA, Kipps TJ (2006) CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood 107(5):1761–1767PubMedCrossRef
30.
go back to reference Fayad L, Keating MJ, Reuben JM, O'Brien S, Lee BN, Lerner S, Kurzrock R (2001) Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood 97(1):256–263PubMedCrossRef Fayad L, Keating MJ, Reuben JM, O'Brien S, Lee BN, Lerner S, Kurzrock R (2001) Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood 97(1):256–263PubMedCrossRef
31.
go back to reference Jewell AP, Worman CP, Giles FJ, Goldstone AH (1997) Serum levels of TNF, IL-6 and sCD23 correlate with changes in lymphocyte count in patients with B-cell chronic lymphocytic leukaemia receiving interferon-alpha therapy. Leuk Lymphoma 24(3–4):327–333PubMed Jewell AP, Worman CP, Giles FJ, Goldstone AH (1997) Serum levels of TNF, IL-6 and sCD23 correlate with changes in lymphocyte count in patients with B-cell chronic lymphocytic leukaemia receiving interferon-alpha therapy. Leuk Lymphoma 24(3–4):327–333PubMed
32.
go back to reference Bojarska-Junak A, Hus I, Szczepanek EW, Dmoszyńska A, Roliński J (2008) Peripheral blood and bone marrow TNF and TNF receptors in early and advanced stages of B-CLL in correlation with ZAP-70 protein and CD38 antigen. Leuk Res 32(2):225–233PubMedCrossRef Bojarska-Junak A, Hus I, Szczepanek EW, Dmoszyńska A, Roliński J (2008) Peripheral blood and bone marrow TNF and TNF receptors in early and advanced stages of B-CLL in correlation with ZAP-70 protein and CD38 antigen. Leuk Res 32(2):225–233PubMedCrossRef
33.
go back to reference Wierda WG, Johnson MM, Do KA, Manshouri T, Dey A, O’Brien S et al (2003) Plasma interleukin 8 level predicts for survival in chronic lymphocytic leukaemia. Br J Haematol 120(3):452–456PubMedCrossRef Wierda WG, Johnson MM, Do KA, Manshouri T, Dey A, O’Brien S et al (2003) Plasma interleukin 8 level predicts for survival in chronic lymphocytic leukaemia. Br J Haematol 120(3):452–456PubMedCrossRef
34.
go back to reference Kara IO, Sahin B, Gunesacar R (2007) Expression of soluble CD27 and interleukins-8 and -10 in B-cell chronic lymphocytic leukemia: correlation with disease stage and prognosis. Adv Ther 24(1):29–40PubMedCrossRef Kara IO, Sahin B, Gunesacar R (2007) Expression of soluble CD27 and interleukins-8 and -10 in B-cell chronic lymphocytic leukemia: correlation with disease stage and prognosis. Adv Ther 24(1):29–40PubMedCrossRef
35.
go back to reference Ennas MG, Moore PS, Zucca M, Angelucci E, Cabras MG, Melis M et al (2008) Interleukin-1B (IL1B) and interleukin-6 (IL6) gene polymorphisms are associated with risk of chronic lymphocytic leukaemia. Hematol Oncol 26(2):98–103PubMedCrossRef Ennas MG, Moore PS, Zucca M, Angelucci E, Cabras MG, Melis M et al (2008) Interleukin-1B (IL1B) and interleukin-6 (IL6) gene polymorphisms are associated with risk of chronic lymphocytic leukaemia. Hematol Oncol 26(2):98–103PubMedCrossRef
36.
go back to reference di Celle PF, Carbone A, Marchis D, Zhou D, Sozzani S, Zupo S, Pini M, Mantovani A, Foa R (1994) Cytokine gene expression in B-cell chronic lymphocytic leukemia: evidence of constitutive interleukin-8 (IL-8) mRNA expression and secretion of biologically active IL-8 protein. Blood 84(1):220–228PubMed di Celle PF, Carbone A, Marchis D, Zhou D, Sozzani S, Zupo S, Pini M, Mantovani A, Foa R (1994) Cytokine gene expression in B-cell chronic lymphocytic leukemia: evidence of constitutive interleukin-8 (IL-8) mRNA expression and secretion of biologically active IL-8 protein. Blood 84(1):220–228PubMed
37.
go back to reference Zheng Z, Venkatapathy S, Rao G, Harrington CA (2002) Expression profiling of B cell chronic lymphocytic leukemia suggests deficient CD1-mediated immunity, polarized cytokine response, altered adhesion and increased intracellular protein transport and processing of leukemic cells. Leukemia 16(12):2429–2437PubMedCrossRef Zheng Z, Venkatapathy S, Rao G, Harrington CA (2002) Expression profiling of B cell chronic lymphocytic leukemia suggests deficient CD1-mediated immunity, polarized cytokine response, altered adhesion and increased intracellular protein transport and processing of leukemic cells. Leukemia 16(12):2429–2437PubMedCrossRef
38.
go back to reference Stratowa C, Löffler G, Lichter P, Stilgenbauer S, Haberl P, Schweifer N, Döhner H, Wilgenbus KK (2001) CDNA microarray gene expression analysis of B-cell chronic lymphocytic leukemia proposes potential new prognostic markers involved in lymphocyte trafficking. Int J Cancer 91(4):474–480PubMedCrossRef Stratowa C, Löffler G, Lichter P, Stilgenbauer S, Haberl P, Schweifer N, Döhner H, Wilgenbus KK (2001) CDNA microarray gene expression analysis of B-cell chronic lymphocytic leukemia proposes potential new prognostic markers involved in lymphocyte trafficking. Int J Cancer 91(4):474–480PubMedCrossRef
39.
go back to reference Cordingley FT, Bianchi A, Hoffbrand AV, Reittie JE, Heslop HE, Vyakarnam A, Turner M, Meager A, Brenner MK (1988) Tumour necrosis factor as an autocrine tumour growth factor for chronic B-cell malignancies. Lancet 1(8592):969–971PubMedCrossRef Cordingley FT, Bianchi A, Hoffbrand AV, Reittie JE, Heslop HE, Vyakarnam A, Turner M, Meager A, Brenner MK (1988) Tumour necrosis factor as an autocrine tumour growth factor for chronic B-cell malignancies. Lancet 1(8592):969–971PubMedCrossRef
40.
go back to reference Lisignoli G, Toneguzzi S, Pozzi C, Piacentini A, Grassi F, Ferruzzi A, Gualtieri G, Facchini A (1999) Chemokine expression by subchondral bone marrow stromal cells isolated from osteoarthritis (OA) and rheumatoid arthritis (RA) patients. Clin Exp Immunol 116(2):371–378PubMedCrossRef Lisignoli G, Toneguzzi S, Pozzi C, Piacentini A, Grassi F, Ferruzzi A, Gualtieri G, Facchini A (1999) Chemokine expression by subchondral bone marrow stromal cells isolated from osteoarthritis (OA) and rheumatoid arthritis (RA) patients. Clin Exp Immunol 116(2):371–378PubMedCrossRef
41.
go back to reference Chauhan D, Uchiyama H, Akbarali Y, Urashima M, Yamamoto K, Libermann TA, Anderson KC (1996) Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood 87(3):1104–1112PubMed Chauhan D, Uchiyama H, Akbarali Y, Urashima M, Yamamoto K, Libermann TA, Anderson KC (1996) Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood 87(3):1104–1112PubMed
42.
go back to reference Binsky I, Haran M, Starlets D, Gore Y, Lantner F, Harpaz N et al (2007) IL-8 secreted in a macrophage migration-inhibitory factor- and CD74-dependent manner regulates B cell chronic lymphocytic leukemia survival. Proc Natl Acad Sci USA 104(33):13408–13413PubMedCrossRef Binsky I, Haran M, Starlets D, Gore Y, Lantner F, Harpaz N et al (2007) IL-8 secreted in a macrophage migration-inhibitory factor- and CD74-dependent manner regulates B cell chronic lymphocytic leukemia survival. Proc Natl Acad Sci USA 104(33):13408–13413PubMedCrossRef
43.
go back to reference Tretter T, Schuler M, Schneller F, Brass U, Esswein M, Aman MJ, Huber C, Peschel C (1998) Direct cellular interaction with activated CD4 T cells overcomes hyporesponsiveness of B-cell chronic lymphocytic leukemia in vitro. Cell Immunol 189(1):41–50PubMedCrossRef Tretter T, Schuler M, Schneller F, Brass U, Esswein M, Aman MJ, Huber C, Peschel C (1998) Direct cellular interaction with activated CD4 T cells overcomes hyporesponsiveness of B-cell chronic lymphocytic leukemia in vitro. Cell Immunol 189(1):41–50PubMedCrossRef
44.
go back to reference Abbas AK, Lichtman AH (2005) Cellular and molecular immunology, 5th edn. Elsevier Saunders, Philadelphia, PA, USA, p 173 Abbas AK, Lichtman AH (2005) Cellular and molecular immunology, 5th edn. Elsevier Saunders, Philadelphia, PA, USA, p 173
Metadata
Title
Chronic lymphocytic leukemia cells induce anti-apoptotic effects of bone marrow stroma
Authors
Márk Plander
Peter Ugocsai
Silvia Seegers
Evelyn Orsó
Albrecht Reichle
Gerd Schmitz
Ferdinand Hofstädter
Gero Brockhoff
Publication date
01-12-2011
Publisher
Springer-Verlag
Published in
Annals of Hematology / Issue 12/2011
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-011-1218-z

Other articles of this Issue 12/2011

Annals of Hematology 12/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.